Neperud J, Mahvash A, Garg N, Murthy R, Szklaruk J. Can imaging patterns of neuroendocrine hepatic metastases predict response yttruim-90 radioembolotherapy? World J Radiol 2013; 5(6): 241-247 [PMID: 23807902 DOI: 10.4329/wjr.v5.i6.241]
Corresponding Author of This Article
Janio Szklaruk, MD, PhD, Department of Diagnostic Radiology, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States. jszklaru@mdanderson.org
Research Domain of This Article
Radiology, Nuclear Medicine & Medical Imaging
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Radiol. Jun 28, 2013; 5(6): 241-247 Published online Jun 28, 2013. doi: 10.4329/wjr.v5.i6.241
Can imaging patterns of neuroendocrine hepatic metastases predict response yttruim-90 radioembolotherapy?
Julia Neperud, Armeen Mahvash, Naveen Garg, Ravi Murthy, Janio Szklaruk
Julia Neperud, Armeen Mahvash, Naveen Garg, Ravi Murthy, Janio Szklaruk, Department of Diagnostic Radiology, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
Author contributions: Neperud J, Mahvash A, Garg N and Szklaruk J contributed to research design; Neperud J, Garg N and Szklaruk J conducted experiments and performed data analysis; all authors wrote the manuscript.
Correspondence to: Janio Szklaruk, MD, PhD, Department of Diagnostic Radiology, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, United States. jszklaru@mdanderson.org
Telephone: +1-713-7453230 Fax: +1-713-7944379
Received: February 22, 2013 Revised: May 3, 2013 Accepted: May 18, 2013 Published online: June 28, 2013 Processing time: 124 Days and 4.9 Hours
Core Tip
Core tip: Treatment modalities for neuroendocrine tumor liver metastases (NETLM) include systemic chemotherapy, surgery, ablation, chemoembolization, and yttrium-90 (90Y) radioembolization. Radioembolotherapy is aimed at delivering high dose of radiation via intra-arterial administration. There are reports of good response rates of NETLM following radioembolization. There are a few reports on the selection criteria based on imaging features. To our knowledge, there are no reports that have evaluated multiple imaging features as selection criteria for 90Y radioembolization. Our goal is to evaluate for a specific imaging feature at presentation that may predict response to treatment. The response will be evaluated using various criteria of tumor response.
